Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06937827 · ClinicalTrials.gov registry record · NA

Transitions of Care Clinic (TOCC)

A NA study of Heart Failure With Preserved Ejection Fraction, sponsored by Hackensack Meridian Health.

Recruiting
Registry status
NA
Development phase
150
Enrollment target
1
Study location

NCT06937827 is a NA study of Heart Failure With Preserved Ejection Fraction that is actively recruiting participants, run by Hackensack Meridian Health. The registered enrollment target is 150 participants, below the 2,285-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06937827, a NA study of Heart Failure With Preserved Ejection Fraction, is actively recruiting participants, sponsored by Hackensack Meridian Health.

RECRUITING
Registry status
NA
Development phase
150 participants
Enrollment target
1
Study location

Study Summary

The transition period from hospital to home is a time of heightened risk for patients to experience adverse events, medication errors, and readmission to the hospital. Patients at the highest risk include older adults and patients with low health literacy, socioeconomic disadvantages, and/or multiple comorbidities. This project proposes to expand the existing Transitions of Care Clinic (TOCC) which was recently introduced in our institution in 2024, to bridge the gap in care between hospital discharge to home and connect discharged patients to their outpatient providers with a focus on patients with heart failure (HF). The existing TOCC, a multidisciplinary team composed of a pharmacist and a nurse practitioner, seeks to improve the services that are currently being provided to patients and enhance the transitions of care process by providing patients with education, tools, and resources to help manage their chronic disease. With this study, we propose to expand TOCC by offering extensive education to patients via iPad videos and providing them with HF tool kits prior to their discharge. We will also assist with scheduling follow appointments with their outpatient providers and follow up with patients after the appointment takes place to re-evaluate their needs and reinforce self management of heart failure. By targeting patients being treated for acute exacerbation of heart failure with preserved ejection fraction (HFpEF), this study aims to facilitate the transition of care, reduce hospital readmissions and improve patients' quality of life and satisfaction. Patients with HFpEF represent a majority of the HF patients that are readmitted at OUMC. HFpEF patients have fewer guideline recommended treatments and represent a vulnerable patient population. The HF tool kits will provide these patients with the essential tools, resources, and log sheets for self-management such as monitoring daily weights, monitoring blood pressure and heart rate. Patients provided with

Interventions

  • BEHAVIORAL HF Kit and Follow-ups

Study Locations (1)

New Jersey

  • Ocean University Medical Center - Brick

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2025-06-26
Est. Completion 2027-04-15
Phase NA

Sponsor

Hackensack Meridian Health

90 total trials

What the Registry Record Tells You About NCT06937827

The ClinicalTrials.gov registry entry for NCT06937827 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,285-participant average among 42 other Heart Failure With Preserved Ejection Fraction trials with a reported enrollment target (93% lower). The listed sponsor is Hackensack Meridian Health, which has 90 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Heart Failure With Preserved Ejection Fraction appearing as the primary indexed condition, and to 1 intervention - of which HF Kit and Follow-ups is the first listed.

NCT06937827 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.

Frequently Asked Questions

What is clinical trial NCT06937827 about?

NCT06937827 is a clinical study titled "Transitions of Care Clinic (TOCC)". The transition period from hospital to home is a time of heightened risk for patients to experience adverse events, medication errors, and readmission to the hospital. Patients at the highest risk include older adults and patients with low health literacy, socioeconomic disadvantages, and/or multipl...

What is the current status of trial NCT06937827?

This trial is currently recruiting. It is a NA study. The enrollment target is 150 participants. The study started on 2025-06-26. Estimated completion is 2027-04-15.

What conditions does trial NCT06937827 study?

This clinical trial studies the following conditions: Heart Failure With Preserved Ejection Fraction.

What interventions are being tested in trial NCT06937827?

The interventions under investigation include: HF Kit and Follow-ups (BEHAVIORAL).

Who is sponsoring clinical trial NCT06937827?

This trial is sponsored by Hackensack Meridian Health, which has 90 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06937827 being conducted?

This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Heart Failure With Preserved Ejection Fraction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.